Current Drug Research Studies being conducted at
Premier Retina Specialists
A Randomized, Double-masked, Phase 3 Study of ABP 938 Efficacy and Safety Compared to Aflibercept (Eylea®) in Subjects with Neovascular Age-related Macular Degeneration
A clinical research study of an investigational drug to treat the neovascular (or wet) form of age-related macular degeneration. Age-related macular degeneration (hereafter referred to as AMD) is one of the major causes of permanent vision loss and blindness in individuals older than 50 years. The retina is the thin layer of cells that lines the back of the eyeball and its role is to sense the light which gets into the eye and enables humans to see. In AMD, the retina gets damaged causing vision impairment. There is no permanent cure for stopping the damage of the retina. Treatment with the investigational drug aims to slow down the progression of disease and to prevent further vision loss.
Future Prospective Studies
We are looking into participation in a study for advanced Dry Macular Degeneration.
We will post more soon.
For further information about studies, please contact the practice and speak to Lu An, the Clinical Trial Director, at extension 201.